Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 23;57(2):188.
doi: 10.3390/medicina57020188.

Perioperative Management of Chronic Antithrombotic Agents in Elective Hip and Knee Arthroplasty

Daniel C Santana  1 , Matthew J Hadad  1 , Ahmed Emara  1 , Alison K Klika  1 , Wael Barsoum  2 , Robert M Molloy  1 , Viktor E Krebs  1 , Michael R Bloomfield  1 , Nicolas S Piuzzi  1
Affiliations
Review

Perioperative Management of Chronic Antithrombotic Agents in Elective Hip and Knee Arthroplasty

Daniel C Santana et al. Medicina (Kaunas). .

Abstract

Total hip and knee arthroplasty are common major orthopedic operations being performed on an increasing number of patients. Many patients undergoing total joint arthroplasty (TJA) are on chronic antithrombotic agents due to other medical conditions, such as atrial fibrillation or acute coronary syndrome. Given the risk of bleeding associated with TJAs, as well as the risk of thromboembolic events in the post-operative period, the management of chronic antithrombotic agents perioperatively is critical to achieving successful outcomes in arthroplasty. In this review, we provide a concise overview of society guidelines regarding the perioperative management of chronic antithrombotic agents in the setting of elective TJAs and summarize the recent literature that may inform future guidelines. Ultimately, antithrombotic regimen management should be patient-specific, in consultation with cardiology, internal medicine, hematology, and other physicians who play an essential role in perioperative care.

Keywords: anticoagulation; arthroplasty; major bleeding; surgical complications; venous thromboembolism.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Algorithm for the perioperative interruption of antithrombotic agents. DOAC: direct oral anticoagulant. INR: international normalized ratio. BID: twice per day.
See this image and copyright information in PMC

References

    1. Barnes G.D., Lucas E., Alexander G.C., Goldberger Z.D. National trends in ambulatory oral anticoagulant use. Am. J. Med. 2015;128:1300–1305.e2. doi: 10.1016/j.amjmed.2015.05.044. - DOI - PMC - PubMed
    1. Wong S.L., Marshall L.Z., Lawson K.A. Direct oral anticoagulant prescription trends, switching patterns, and adherence in Texas medicaid. Am. J. Manag. Care. 2018;24:SP309–SP314. - PubMed
    1. Zhu J., Alexander G.C., Nazarian S., Segal J.B., Wu A.W. Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010–2017. Pharmacotherapy. 2018;38:907–920. doi: 10.1002/phar.2158. - DOI - PMC - PubMed
    1. Mega J.L., Simon T. Pharmacology of antithrombotic drugs: An assessment of oral antiplatelet and anticoagulant treatments. Lancet. 2015;386:281–291. doi: 10.1016/S0140-6736(15)60243-4. - DOI - PubMed
    1. Sloan M., Premkumar A., Sheth N.P. Projected volume of primary total joint arthroplasty in the USA, 2014 to 2030. J. Bone Jt. Surg. Am. 2018;100:1455–1460. doi: 10.2106/JBJS.17.01617. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources